Email
Print
Fibromyalgia Treatment Market - Forecast(2024 - 2030)
Fibromyalgia Treatment Market Overview:
The Fibromyalgia Treatment Market was valued at 3.200 billion in 2022, and is projected to reach 4.200 billion by 2030, growing at a CAGR of 4% from 2023 to 2030.
The fibromyalgia treatment market was characterized by ongoing research and development efforts to address the complex nature of the condition. Fibromyalgia is a chronic disorder causing widespread musculoskeletal pain, fatigue, and cognitive difficulties. However, there was no specific cure for fibromyalgia, and treatment primarily focused on managing symptoms and improving patients' quality of life.
The market saw a range of pharmaceutical and non-pharmaceutical interventions, including pain medications, antidepressants, and physical therapy. Additionally, alternative therapies such as acupuncture, yoga, and mindfulness techniques gained popularity as complementary treatment options.
The prevalence of fibromyalgia and its impact on patients' lives drove the market's growth, prompting companies and researchers to invest in innovative therapies and better understanding the underlying mechanisms. Nevertheless, a comprehensive and definitive treatment approach remained elusive, and managing fibromyalgia continued to be a multidisciplinary challenge.
Market Snapshot:
Fibromyalgia Treatment Market - Report Coverage:
The “Fibromyalgia Treatment Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Fibromyalgia Treatment Market.
| Attribute | Segment |
|---|---|
By Type |
|
By Distribution |
|
By End-user |
|
By Diagnosis |
|
By Treatment |
|
By Geography |
|
Fibromyalgia Treatment Market - Top Trends:
Personalized Medicine: Researchers were exploring individualized treatment approaches, considering patients' specific symptoms and underlying mechanisms. This approach aimed to improve treatment efficacy and minimize side effects by tailoring therapies to each patient's unique needs.
Non-Pharmacological Therapies: Non-drug treatments like cognitive-behavioral therapy (CBT), physical therapy, and exercise were gaining prominence in fibromyalgia management. These approaches focused on improving patients' coping mechanisms, physical fitness, and overall well-being.
Cannabinoids: There was growing interest in exploring the potential of cannabinoids (e.g., CBD and THC) for pain relief and symptom management in fibromyalgia. However, research was ongoing to understand their safety, efficacy, and long-term effects better.
Virtual Health Solutions: The COVID-19 pandemic accelerated the adoption of telemedicine and virtual health solutions. These technologies facilitated remote consultations, making it more convenient for patients to access specialized care and support.
Research into New Drug Classes: Pharmaceutical companies were investigating novel drug classes targeting specific pathways related to pain processing and neurology. These included NMDA receptor antagonists, serotonin-norepinephrine reuptake inhibitors (SNRIs), and others.
The Fibromyalgia Treatment Market - Company Analysis:
Pfizer Inc: Pfizer was one of the leading pharmaceutical companies working on fibromyalgia treatments. They developed Lyrica (pregabalin), which is an FDA-approved medication for fibromyalgia pain management.
Eli Lilly and Company: Eli Lilly was actively engaged in research and development efforts to explore potential treatments for fibromyalgia, including new pain medications and biologic therapies.
Teva Pharmaceutical Industries Ltd: Teva was involved in the production of generic medications, including generic versions of drugs used in fibromyalgia treatment, making them more affordable and accessible to patients.
Tonix Pharmaceuticals: Tonix Pharmaceuticals was exploring potential new therapies for fibromyalgia, including TNX-102 SL, a sublingual formulation of cyclobenzaprine.
Aptinyx Inc: Aptinyx was engaged in research and clinical trials to investigate NMDA receptor modulators for the treatment of fibromyalgia.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the are key strategies adopted by players in the Fibromyalgia Treatment Market Report. The top 10 companies in this industry are listed below:
Sun Pharmaceutical Industries Limited
AbbVie Inc
Lupin Limited
Teva Pharmaceutical Industries Ltd
Viatris Inc
Amneal Pharmaceuticals LLC
Eli Lilly and Company
Novartis AG
Abbott Laboratories
Zydus Lifesciences Limited
Scope of Report:
| Report Metric | Details |
|---|---|
Base Year Considered | 2022 |
Forecast Period | 2023 – 2030 |
CAGR | 4.5% |
Market Size in 2030 | 4100 million |
Segments Covered | By Type, By Distribution, By End user, By Diagnosis, By Treatment, By Geography |
Geographies Covered |
|
Key Market Players |
|
For more Lifesciences and Healthcare Market reports, please click here
1. Fibromyalgia Treatment Market - Overview
1.1. Definitions and Scope
2. Fibromyalgia Treatment Market - Executive Summary
3. Fibromyalgia Treatment Market - Comparative Analysis
3.1. Company Benchmarking - Key Companies
3.2. Global Financial Analysis - Key Companies
3.3. Market Share Analysis - Key Companies
3.4. Patent Analysis
3.5. Pricing Analysis
4. Fibromyalgia Treatment Market - Start-up Companies Scenario (Premium)
4.1. Key Start-up Company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Venture Capital and Funding Scenario
5. Fibromyalgia Treatment Market – Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing Business Index
5.3. Case Studies of Successful Ventures
6. Fibromyalgia Treatment Market - Forces
6.1. Market Drivers
6.2. Market Constraints
6.3. Market Challenges
6.4. Porter's Five Force Model
6.4.1. Bargaining Power of Suppliers
6.4.2. Bargaining Powers of Customers
6.4.3. Threat of New Entrants
6.4.4. Rivalry Among Existing Players
6.4.5. Threat of Substitutes
7. Fibromyalgia Treatment Market – Strategic Analysis
7.1. Value Chain Analysis
7.2. Opportunities Analysis
7.3. Market Life Cycle
8. Fibromyalgia Treatment Market – By Type (Market Size – $Million/$Billion)
8.1. ANTIEPILEPTIC
8.1.1. Market Trends by Region
8.1.2.Market Share & Forecast by Region
8.2. ANTIDEPREESANT
8.2.1. Market Trends by Region
8.2.2. Market Share & Forecast by Region
8.3. MUSCLE RELAXANTS
8.3.1. Market Share & Forecast by Region
8.3.2. Market Share & Forecast by Region
8.4. ANALGESIC
8.4.1. Market Share & Forecast by Region
8.4.2. Market Share & Forecast by Region
8.5. Others
9. Fibromyalgia Treatment Market – BY DISTRIBUTION (Market Size – $Million/$Billion)
9.1. HOSPITAL PHARMACIES
9.1.1. Market Trends by Region
9.1.2. Market Share & Forecast by Region
9.2. RETAIL PHARMACIES Market Trends by Region
9.2.1. Market Trends by Region
9.2.2. Market Share & Forecast by Region
9.3. ONLINE PHARMACIES
9.3.1. Market Trends by Region
9.3.2. Market Share & Forecast by Region
10. Fibromyalgia Treatment Market – By End-User (Market Size – $Million/$Billion)
10.1. Hospital
10.1.1. Market Trends by Region
10.1.2. Market Share & Forecast by Region
10.2. Clinics
10.2.1. Market Trends by Region
10.2.2 . Market Share & Forecast by Region
10.3. Diagnostic Censers
10.3.1. Market Trends by Region
10.3.2. Market Share & Forecast by Region
11. Fibromyalgia Treatment Market – By Diagnosis (Market Size – $Million/$Billion)
11.1 Laboratory Evaluation
11.1.1. Market Trends by Region
11.1.2. Market Share & Forecast by Region
11.2 Presence of Central Sensitization
11.2.1. Market Trends by Region
11.2.2 . Market Share & Forecast by Region
12. Fibromyalgia Treatment Market – By Treatment (Market Size – $Million/$Billion)
12.1 Symptomatic Treatment
12.1.1. Market Trends by Region
12.1.2. Market Share & Forecast by Region
12.2. Targeted Treatment
12.2.1. Market Trends by Region
12.2.2. Market Share & Forecast by Region
13. Fibromyalgia Treatment Market – by Geography (Market Size – $Million/$Billion)
13.1. North America
13.1.1. The U.S.
13.1.2. Canada
13.2. Europe
13.2.1. UK
13.2.2. Germany
13.2.3. France
13.2.4. Italy
13.2.5. Spain
13.2.6. Russia
13.2.7. Rest of Europe
13.3. Asia-Pacific
13.3.1. China
13.3.2. India
13.3.3. Japan
13.3.4. South Korea
13.3.5. Australia & New Zealand
13.3.6. Rest of Asia-Pacific
13.4. South America
13.4.1. Brazil
13.4.2. Argentina
13.4.3. Chile
13.4.4. Colombia
13.4.5. Rest of South America
13.5. Rest of the World
13.5.1. Middle East
13.5.2. Africa
14. Fibromyalgia Treatment Market – Entropy
15. Fibromyalgia Treatment Market – Industry/Segment Competition Landscape Premium
15.1. Market Share Analysis
15.1.1. Market Share by Product Type – Key Companies
15.1.2. Market Share by Region – Key Companies
15.1.3. Market Share by Country – Key Companies
15.2. Competition Matrix
15.3. Best Practices for Companies
16. Fibromyalgia Treatment Market – Key Company List by Country Premium
17. Fibromyalgia Treatment Market - Company Analysis
17.1. Sun Pharmaceutical Industries Limited
17.2. AbbVie Inc
17.3. Lupin Limited
17.4. Teva Pharmaceutical Industries Ltd
17.5. Viatris Inc
17.6. Amneal Pharmaceuticals LLC
17.7. Eli Lilly and Company
17.8. Novartis AG
17.9. Abbott Laboratories
17.10. Zydus Lifesciences Limited
17.11. VIRIOS THERAPEUTICS
17.12. ASTELLAS PHARMA
17.13. INTEC PHARMA S.R.O.
17.14. APTINYX INC.
17.15. PRISMIC PHARMACEUTICALS
17.16. ALLEGRAN
17.17. Innovative Med Concepts
17.18. Pfizer, Inc
17.19. Roche
"Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape.
The Fibromyalgia Treatment Market is projected to grow at 4% CAGR during the forecast period 2023-2030.
Fibromyalgia Treatment Market size is projected to reach 4.100 billion by 2030
Sun Pharmaceutical Industries Limited, AbbVie Inc, Lupin Limited, Teva Pharmaceutical Industries Ltd, Viatris Inc, Amneal Pharmaceuticals LLC, Eli Lilly and Company